Dec. 01, 2025 -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA. The new analyse

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection for ongoing pivotal FORTIFI-HN01 clinical trial of ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Company to host conference call and webcast on Saturday, December 6, 2025 at 9:00 a.m. ET Dec. 01, 2025 -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

Nov. 25, 2025 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking p

Nov. 26, 2025 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that its CEO, Motti Farbstein will present at NobleCon21—Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference—at Florida Atlantic University, Executive Education Complex, in Boca Raton, Floria—on Wednesday, December 3rd, 2025 at 12:30 PM ET. Mr. Farb

Nov. 26, 2025 -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series C-1 Warrants (the "Series C-1 Warrants") to purchase up to 4,025,000 shares of the Co

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2 AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI®

Nov. 28, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07

Nov. 24, 2025 -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company’s novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), b

Nov. 27, 2025 -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune di

Nov. 26, 2025 -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announces substantial progress in its custom integration pipeline, currently valued at approximately $3 million, signaling significant momentum in the life sciences sector. The company reports ten active projects across its SteraMist Integrated System (SIS) and Custom Engineered System (CES) platforms, serving both new and existing customers. The advancement reflects TOMI's strategic positioning as a turnkey solution provider